HomeCompareQLGN vs KMB

QLGN vs KMB: Dividend Comparison 2026

QLGN yields 62.31% · KMB yields 4.00%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 QLGN wins by $701.0K in total portfolio value
10 years
QLGN
QLGN
● Live price
62.31%
Share price
$3.21
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$729.0K
Annual income
$175,361.30
Full QLGN calculator →
KMB
KMB
● Live price
4.00%
Share price
$50.00
Annual div
$2.00
5Y div CAGR
5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$899.19
Full KMB calculator →

Portfolio growth — QLGN vs KMB

📍 QLGN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodQLGNKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, QLGN + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
QLGN pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

QLGN
Annual income on $10K today (after 15% tax)
$5,295.95/yr
After 10yr DRIP, annual income (after tax)
$149,057.10/yr
KMB
Annual income on $10K today (after 15% tax)
$340.00/yr
After 10yr DRIP, annual income (after tax)
$764.31/yr
At 15% tax rate, QLGN beats the other by $148,292.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of QLGN + KMB for your $10,000?

QLGN: 50%KMB: 50%
100% KMB50/50100% QLGN
Portfolio after 10yr
$378.5K
Annual income
$88,130.25/yr
Blended yield
23.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

QLGN
No analyst data
Altman Z
-5.6
Piotroski
3/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+146.0% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

QLGN buys
0
KMB buys
0
No recent congressional trades found for QLGN or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricQLGNKMB
Forward yield62.31%4.00%
Annual dividend / share$2.00$2.00
Payout ratio50%50%
1-year div growth0%5%
5-year div CAGR0%5%
Portfolio after 10y$729.0K$28.0K
Annual income after 10y$175,361.30$899.19
Total dividends collected$608.8K$6.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: QLGN vs KMB ($10,000, DRIP)

YearQLGN PortfolioQLGN Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$16,931$6,230.53$11,120$420.00+$5.8KQLGN
2$27,974$9,858.52$12,357$458.31+$15.6KQLGN
3$45,156$15,223.51$13,721$499.76+$31.4KQLGN
4$71,283$22,966.14$15,227$544.58+$56.1KQLGN
5$110,155$33,882.50$16,885$593.02+$93.3KQLGN
6$166,800$48,934.07$18,713$645.34+$148.1KQLGN
7$247,726$69,249.85$20,724$701.81+$227.0KQLGN
8$361,186$96,119.21$22,938$762.73+$338.2KQLGN
9$517,443$130,974.20$25,372$828.41+$492.1KQLGN
10$729,026$175,361.30$28,047$899.19+$701.0KQLGN

QLGN vs KMB: Complete Analysis 2026

QLGNStock

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Full QLGN Calculator →

KMBConsumer Staples

KMB is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in KMB shares.

Full KMB Calculator →
📬

Get this QLGN vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

QLGN vs SCHDQLGN vs JEPIQLGN vs OQLGN vs KOQLGN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.